The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response
Open accessAbstract
SUMMARY Apoptosis is a highly regulated form of cell death that controls normal homeostasis as well as the anti-tumor activity of many chemotherapeutic agents. Commitment to death via the mitochondrial apoptotic pathway requires activation of the mitochondrial pore-forming proteins BAK or BAX. Activation can be effected by the activator BH3-only proteins BID or BIM, which have been considered to be functionally redundant in this role. Herein, we show that significant activation preferences exist between these proteins: BID preferentially activates BAK while BIM preferentially activates BAX. Furthermore, we find that cells lacking BAK are relatively resistant to agents that require BID activation for maximal induction of apoptosis including topoisomerase inhibitors and TRAIL. Consequently, patients with tumors that harbor a loss of BAK1 exhibit an inferior response to topoisomerase inhibitor treatment in the clinic. Therefore, BID and BIM have non-overlapping roles in the induction of apoptosis via BAK and BAX, affecting chemotherapy response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Luo, X., Budihardjo, I., Zou, H., Slaughter, C., & Wang, X. (1998) · Cell · doi:10.1016/s0092-8674(00)81589-5 · Cited by 3,626
Mitochondria and cell death: outer membrane permeabilization and beyond
Tait, S. W. G., & Green, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2952 · Cited by 2,593
Programmed Cell Death in Animal Development and Disease
Fuchs, Y., & Steller, H. (2011) · Cell · doi:10.1016/j.cell.2011.10.033 · Cited by 1,915
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881
Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677
Self-citationLindsten, T., Ross, A. J., King, A., Zong, W.-X., Rathmell, J. C., Shiels, H. A., Ulrich, E., Waymire, K. G., Mahar, P., Frauwirth, K., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00136-2 · Cited by 1,489
Bossy‐Wetzel, E., Newmeyer, D. D., & Green, D. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.1.37 · Cited by 1,225
Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis
Yin, X.-M., Wang, K., Gross, A., Zhao, Y., Zinkel, S., Klocke, B., Roth, K. A., & Korsmeyer, S. J. (1999) · Nature · doi:10.1038/23730 · Cited by 1,004
Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies
Kim, H., Rafiuddin-Shah, M., Tu, H.-C., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J.-D., & Cheng, E. H.-Y. (2006) · Nature Cell Biology · doi:10.1038/ncb1499 · Cited by 874
BAX activation is initiated at a novel interaction site
Gavathiotis, E., Suzuki, M., Davis, M. L., Pitter, K., Bird, G. H., Katz, S. G., Tu, H.-C., Kim, H., Cheng, E. H.-Y., Tjandra, N., et al. (2008) · Nature · doi:10.1038/nature07396 · Cited by 700
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Mitochondria as multifaceted regulators of cell death
Bock, F. J., & Tait, S. W. G. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0173-8 · Cited by 2,450
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111
Self-citationVyas, S., Zaganjor, E., & Haigis, M. C. (2016) · Cell · doi:10.1016/j.cell.2016.07.002 · Cited by 1,735
BCL-2 family proteins: changing partners in the dance towards death
Kale, J., Osterlund, E. J., & Andrews, D. W. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.186 · Cited by 1,574
Self-citationBax, Bak and beyond — mitochondrial performance in apoptosis
Peña‐Blanco, A., & García‐Sáez, A. J. (2018) · The FEBS Journal · doi:10.1111/febs.14186 · Cited by 930
Mitochondrial apoptosis: killing cancer using the enemy within
Lopez, J., & Tait, S. W. G. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.85 · Cited by 784
Mechanisms of BCL-2 family proteins in mitochondrial apoptosis
Czabotar, P. E., & Garcia-Saez, A. J. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00629-4 · Cited by 680
BCL-2 proteins and apoptosis: Recent insights and unknowns
Edlich, F. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.190 · Cited by 632
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
Targeting BCL-2 regulated apoptosis in cancer
Campbell, K. J., & Tait, S. W. G. (2018) · Open Biology · doi:10.1098/rsob.180002 · Cited by 545
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.042 · Cited by 378
Self-citationMitochondria—Judges and Executioners of Cell Death Sentences
Bhola, P. D., & Letai, A. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.019 · Cited by 326
Self-citationWhy do BCL-2 inhibitors work and where should we use them in the clinic?
Montero, J., & Letai, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.183 · Cited by 327
Self-citationPhysiological and pharmacological modulation of BAX
Spitz, A. Z., & Gavathiotis, E. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.001 · Cited by 317
Orthologous CRISPR–Cas9 enzymes for combinatorial genetic screens
Najm, F. J., Strand, C., Donovan, K. F., Hegde, M., Sanson, K. R., Vaimberg, E. W., Sullender, M. E., Hartenian, E., Kalani, Z., Fusi, N., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4048 · Cited by 279
Mitochondrial Shape Governs BAX-Induced Membrane Permeabilization and Apoptosis
Renault, T. T., Floros, K. V., Elkholi, R., Corrigan, K.-A., Kushnareva, Y., Wieder, S. Y., Lindtner, C., Serasinghe, M. N., Asciolla, J. J., Buettner, C., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.10.028 · Cited by 217
VDAC2 enables BAX to mediate apoptosis and limit tumor development
Chin, H. S., Li, M. X., Tan, I. K. L., Ninnis, R. L., Reljic, B., Scicluna, K., Dagley, L. F., Sandow, J. J., Kelly, G. L., Samson, A. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07309-4 · Cited by 196
Differential retrotranslocation of mitochondrial Bax and Bak
Todt, F., Cakir, Z., Reichenbach, F., Emschermann, F., Lauterwasser, J., Kaiser, A., Ichim, G., Tait, S. W., Frank, S., Langer, H. F., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201488806 · Cited by 172
Brouwer, J. M., Westphal, D., Dewson, G., Robin, A. Y., Uren, R. T., Bartolo, R., Thompson, G. V., Colman, P. M., Kluck, R. M., & Czabotar, P. E. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.07.016 · Cited by 161
“Our results are not inconsistent with recent studies suggesting that Bak is preferentially activated by Bid (Sarosiek et al., 2013), although peptide length differences may also contribute in our studies.”
ResultPhysiological and Pharmacological Control of BAK, BAX, and Beyond
Luna-Vargas, M. P. A., & Chipuk, J. E. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.07.002 · Cited by 142
Organelle degradation in the lens by PLAAT phospholipases
Morishita, H., Eguchi, T., Tsukamoto, S., Sakamaki, Y., Takahashi, S., Saito, C., Koyama-Honda, I., & Mizushima, N. (2021) · Nature · doi:10.1038/s41586-021-03439-w · Cited by 111
Motifs of VDAC2 required for mitochondrial Bak import and tBid-induced apoptosis
Naghdi, S., Várnai, P., & Hajnóczky, G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510574112 · Cited by 96
Anderson, G. R., Winter, P. S., Lin, K. H., Nussbaum, D. P., Cakir, M., Stein, E. M., Soderquist, R. S., Crawford, L., Leeds, J. C., Newcomb, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.006 · Cited by 80
“BH3 profiling BH3 profiling was performed as previously described (Sarosiek et al., 2013).”
MethodDistribution and Apoptotic Function of Outer Membrane Proteins Depend on Mitochondrial Fusion
Weaver, D., Eisner, V., Liu, X., Várnai, P., Hunyady, L., Gross, A., & Hajnóczky, G. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.048 · Cited by 58
“It is constitutively present in the OMM in cells containing VDAC2 and mediates the acute phase of Bid-induced OMM permeabilization, whereas Bax, which is commonly cytosolic in healthy cells, inserts and oligomerizes at the OMM more slowly (Roy et al., 2009a; Sarosiek et al., 2013).”
Gutierrez-Martinez, P., Hogdal, L., Nagai, M., Kruta, M., Singh, R., Sarosiek, K., Nussenzweig, A., Beerman, I., Letai, A., & Rossi, D. J. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0054-y · Cited by 60
Self-citationAnderson, G. R., Wardell, S. E., Cakir, M., Crawford, L., Leeds, J. C., Nussbaum, D. P., Shankar, P. S., Soderquist, R. S., Stein, E. M., Tingley, J. P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aae0348 · Cited by 53
Metadata
- Authors
- Sarosiek, K. A., Chi, X., Bachman, J. A., Sims, J. J., Montero, J., Patel, L., Flanagan, A., Andrews, D. W., Sorger, P., & Letai, A.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 51
- Issue
- 6
- Pages
- 751-765
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W2165179086
- Cited by
- 247
- References
- 12
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.